Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights

Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer. Although the possible availability of...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, D'Angelo, Alberto, Roudi, Raheleh, Petrioli, Roberto, Mini, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637676/
https://www.ncbi.nlm.nih.gov/pubmed/31354820
http://dx.doi.org/10.1155/2019/5692317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637676/
https://www.ncbi.nlm.nih.gov/pubmed/31354820
http://dx.doi.org/10.1155/2019/5692317

Ejemplares similares